Literature DB >> 23456526

A rare cytogenetic presentation of acute myeloid leukemia (AML-M2).

Prasanna Kumari1, Bidadi LingappaKavitha, Chintaparthi Obula Reddy, Maiana Mangalagowri, Danem Satienariana Madhumathi, Madaiah Mahadeva Prasad, Hanumanthappa Vijay Raghavendra, Chennagiri Shinivasa Murthy Premalata, Kuntejowdahalli Channaviriappa Lakshmaiah, Seyed Hashem Mir Mazloumi.   

Abstract

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) generating the AML1/ETO fusion gene on 8q22 is a distinct type of AML t(8;21) category (WHO)/AML-M2 (FAB), generally associated with a favourable prognosis. Variant additional chromosomal abnormalities are frequently reported. We report three adult cases of this category with unusual karyotype. Bone marrow cytogenetics of case no. 1: 45,X,-Y, t(8;21)(q13;q22) with a novel breakpoint of chromosome 8 at (q13). Case no. 2: 46,X,t(X;2)(q22;q37),t(3;7)(q21;q36),t(5;14)(p15;q11),del(8)(q22) a complex rearrangement without the involvement of chromosome 21. Case no. 3: 49,XX,+5, t(8;21)(q22;q22), +16, +der(21)t(8;21)(q22;q22) with additional der(21). Endometrial in this case which was positive for myeloperoxidase (MPO) and CD117 conforming the AML infiltration. All are morphologically AML with t(8;21). Relevant literature in cytogenetic of AML-M2 is reviewed. The molecular mechanism involved in unusual rearrangements and clinical significance of them are subjected for further studies.
© 2012 Tehran University of Medical Sciences. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23456526

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  2 in total

1.  Development and evaluation of LAMP, CPA and IMSA methods for rapid detection of the AML1/ETO fusion gene in acute myeloid leukemia.

Authors:  Zhigang Yang; Wenxin Liu; Haiyan Liang; Ruiting Wen; Yuming Zhang
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

Review 2.  Rare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to Therapy.

Authors:  Mohammad Shahjahani; Elahe Khodadi; Mohammad Seghatoleslami; Javad Mohammadi Asl; Neda Golchin; Zeynab Deris Zaieri; Najmaldin Saki
Journal:  Oncol Rev       Date:  2015-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.